-
Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China
•
China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement with US pharmaceutical giant Eli Lilly and Company (NYSE: LLY). The agreement pertains to Lilly’s non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, Jaypirca (pirtobrutinib). Financial details of the agreement have not been disclosed. Under the terms,…
-
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
•
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China, has announced that it has received approval from the US Food and Drug Administration (FDA) to commence a Phase II clinical study for its RIPK2 inhibitor, AC-101, in the treatment of ulcerative colitis (UC). Design…
-
EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease
•
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently recommended the potential approval of Omvoh (mirikizumab) by US pharmaceutical giant Eli Lilly and Company (NYSE: LLY). This treatment is intended for adults with moderately to severely active Crohn’s disease who have not responded adequately…
-
Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review
•
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and Drug Administration (FDA) has accepted its clinical filing for WP107 (huperzine A), an in-house developed drug, for review. The drug is intended to treat generalized myasthenia gravis (gMG), a serious neuromuscular disorder. WP107: A Promising…
-
Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project
•
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on the Hong Kong Stock Exchange, following approval from its board of directors. Concurrently, the company has entered into a significant agreement with Chongqing Hi-tech Industrial Development Zone and Chongqing CAPC PHARM Big Health Private Equity…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from the National Medical Products Administration (NMPA) to proceed with clinical trials for its therapeutic biologic product, SHR-2173, in the treatment of lupus nephritis (LN). SHR-2173: A Novel Treatment for Lupus NephritisSHR-2173 is an in-house developed…
-
Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership
•
Neusoft Medical Systems Co., Ltd, a prominent Chinese medical technology company, has signed an agreement with Xiamen University to establish a joint research and development (R&D) center focused on magnetic resonance imaging (MRI) technology. Xiamen University’s Role in MRI Technology DevelopmentXiamen University, known for its strengths in talent cultivation, basic…
-
Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration
•
Neusoft Medical Systems Co., Ltd, a leading Chinese medical technology company, has announced a strategic agreement with the Center for Information of the National Medical Products Administration (NMPA) of China. The collaboration aims to conduct in-depth research, innovative application, and practice exploration of artificial intelligence (AI) in the realm of…
-
Grand Pharmaceutical’s STC3141 Sepsis Therapy Completes Phase II Patient Enrollment
•
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment and dosing in its Phase II study for STC3141, a sepsis therapy developed by Grand Medical Pty Ltd, the company’s innovative drug R&D center in Australia. The preliminary results of the study are anticipated by…
-
Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors
•
On December 13, 2024, Innovent Biologics, Inc. (HKG: 1801) registered a Phase I clinical trial for IBI3009 on the drug clinical trial registration and information public platform. The trial will investigate the efficacy of IBI3009 in treating small cell lung cancer (SCLC) and other neuroendocrine tumors. Exploring Biomarkers and Efficacy…
-
Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review
•
On December 14th, the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) announced that it has accepted the market application for Zhejiang Huahai Pharmaceutical Co., Ltd’s (SHA: 600521) adalimumab biosimilar injection. Adalimumab is a fully human anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody. The Role of TNF-α in…
-
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
•
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt of a $10 million clinical milestone payment from Exelixis following the progress of its XL309 (ISM3091) project in the clinical stage. XL309 is a selective, oral USP1 small molecule inhibitor discovered by Insilico Medicine using…
-
Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA
•
Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for TransCon hGH (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). The FDA’s decision is anticipated by the Prescription Drug User Fee…
-
Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the first half of 2024, ending September 30, 2023. The company recorded revenues of RMB 14.273 billion (USD 1.96 billion) and profits of RMB 769 million (USD 106 million), marking an increase of 10.2% and 72.8%…
-
Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
•
Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on its label extension bid for Ozempic (once-weekly subcutaneous semaglutide). The company is seeking to expand the indication of the GLP-1 receptor…
-
Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
•
Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I study to assess the preliminary efficacy and safety of its BAY3498264, a selective SOS1 inhibitor, when combined with sotorasib in patients with advanced KRAS G12C-mutated solid tumors. BAY3498264: A Potential Therapeutic Agent for KRAS-Mutant CancersBAY3498264…
-
CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255
•
Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China’s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS). Category…
-
Johnson & Johnson MedTech’s Impella Heart Pumps Gain FDA Approval for Pediatric Heart Failure
•
US major Johnson & Johnson MedTechhas announced receiving premarket approval (PMA) from the US Food and Drug Administration (FDA) for its Impella 5.5 with SmartAssist and Impella CP with SmartAssist heart pumps. This approval expands their indications to include specific pediatric patients with symptomatic acute decompensated heart failure (ADHF) and…
-
Pfizer’s Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial
•
US pharmaceutical major Pfizer Inc. (NYSE: PFE) and Alliance Foundation Trials, LLC (AFT) have announced positive results from the Phase III PATINA trial for Ibrance (palbociclib), a CDK4/6 inhibitor. The trial data indicated that incorporating Ibrance into the standard-of-care first-line maintenance therapy—following induction chemotherapy—resulted in a statistically significant and clinically…
-
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
•
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement with CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093). The agreement secures BeiGene the global development, manufacturing, and commercialization rights to CSPC’s methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH2039. Financial Details and Milestones of the AgreementAs per…
